Impact Factor
3.03
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.52
149 total citations
h5-index
18
h5 depth signal
Cited share
71.9%
46 of 64
Total citations
149
Citation footprint
Metric signal
1.98
External metric anchor
Self-citation
0.7%
1 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
286
Italy
83
United States
19
South Korea
19
Iran
11
Citing Fields of Research
Oncology
163
Noncoding RNA
82
Lung Cancer
82
Liver & Colon Cancer
79
Cancer & Development
73
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,315
Articles tracked across the journal lifetime
Indexed publication set
64
46 cited publications
Last 12 months
31
3.4 publications/month
Open access share
100.0%
31 OA publications in the last year
Leading citing country
China
286 citing publications
Leading citing field
Oncology
163 citing publications
Latest tracked publication
10 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Jan./Apr. 1986-
v1n1, Jan./Apr. 1986-
Active Coverage
Research Focus & Classification
Indexed Subjects
Noncoding RNA
Oncology
Lung Cancer
Cancer & Development
Liver & Colon Cancer
Immunology
Broad Categories
Biochemistry
Neoplasms
Noncoding RNA
Immunology
Hematology
Cancer, Autophagy & Apoptosis
Lung Cancer
Immunotherapy
MeSH Descriptors
Antigens, Neoplasm
Cell Transformation, Neoplastic
Histocytochemistry
Immunologic Techniques
Receptors, Cell Surface
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/03936155261494616
Open DOI
Causal association between fibroblast growth factors (FGFs) and gastric cancer: A two-sample Mendelian randomization study
Objective: To investigate the causal relationships between fibroblast growth factors (FGFs) and gastroesophageal cancers—specifically gastric cancer (GC), cardia cancer (CC), and esophageal cancer (EC)—using a two-sample Mendelian random...
02
DOI 10.1177/03936155261492332
Open DOI
The European cancer landscape: A focused review of epidemiology, prevention, inequalities and innovation
This review provides a focused overview of the current cancer landscape in Europe, addressing epidemiological trends, cancer-related costs, prevention and early detection, inequalities in access to care, and the implementation of therape...
03
DOI 10.1177/03936155261476073
Open DOI
Molecular biomarkers for early-stage hepatocellular carcinoma: Clinical applications beyond alpha-fetoprotein
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related death worldwide, owing to late-stage diagnosis and underlying liver disease that limits curative treatment options. Conventional surveillance and diagnostic strateg...
04
DOI 10.1177/03936155261471908
Open DOI
Multigene testing to guide clinical adjuvant decisions in breast cancer: An overview focused on the assessment of the quality of evidence with the grading of recommendations assessment, development and evaluation (GRADE) approach
Multigene tests have emerged as valuable tools in guiding adjuvant chemotherapy decisions for patients with ER-positive/HER2-negative early breast cancer. This study applied the Grading of Recommendations Assessment, Development and Eval...
05
DOI 10.1177/03936155261488957
Open DOI
Integrative genetic and transcriptomic analyses prioritize CDC16 as a candidate marker for gastric cancer
Background: Gastric cancer (GC) remains a major cause of cancer-related mortality, and biomarkers for early detection are needed. Methods: Stomach and blood expression quantitative trait loci were integrated with two GC genome-wide assoc...
06
07
DOI 10.1177/03936155261481059
Open DOI
Concordance of PD-1 expression on paired peripheral and bone marrow T cells: Surrogate potential and clinical implications in DLBCL
Background: The PD-1/PD-L1 axis represents a key mechanism of tumor immune evasion. However, its expression across different immune compartments and clinical implications in DLBCL patients remain unclear. Methods: This study included 67 ...
08
DOI 10.1177/03936155261465683
Open DOI
Single-cell multi-omics reveals NUF2 as a potential biomarker associated with the high-lactylation malignant state in osteosarcoma
Background: Lactylation has emerged as a crucial post-translational modification that influences oncogenesis and tumor progression. However, its intratumoral heterogeneity in osteosarcoma is not well characterized. Methods: Single-cell m...
09
DOI 10.1177/03936155261417362
Open DOI
Luminex assay of plasma IL-6, TNF-α, leptin, and adiponectin: Impact of anticoagulants, single-well analysis, and freeze–thaw stability
Background: Chronic inflammation from visceral obesity contributes to metabolic disorders and cancer through cytokine imbalance. Accurate cytokine measurement is crucial to understand these links. This study examined challenges in quanti...
10
DOI 10.1177/03936155261451883
Open DOI
PFKP: A biomarker for prognosis, response to treatment and immune function of breast cancer
Background: Phosphofructokinase-platelet (PFKP) is a rate-limiting enzyme in glycolysis. PFKP is highly expressed across many cancer types including breast cancer. Purpose: To assess the extent to which PFKP can be a prognostic indicator...
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with v. 26, no. 4 (2011)
Also issued online.